Bayesian analysis links cefepime with increased mortality

• The Bayesian meta-analysis showed an association of cefepime with increased mortality
• The probability of exceeding the risk is 98.6% (OR>1 – 94.4%)
• Experts recommend optimizing the dose rather than completely abandoning the medication.

Cefepime is a broad-spectrum beta-lactam antibiotic often used in intensive care for treating severe infections. Despite its effectiveness, safety concerns regarding the medication remain relevant, especially in the context of increasing bacterial resistance.

In a recently published study in JAMA Network Open, researchers conducted a Bayesian meta-analysis of randomized clinical trials comparing cefepime with other members of the beta-lactam group. The Bayesian approach allows for the assessment of the probability of a hypothesis, taking into account both the study data and prior assumptions, which is particularly valuable when there is a limited number of high-quality randomized studies.

Key Findings

The analysis showed that the posterior probability that the use of cefepime is associated with a higher mortality from all causes is 98.6%. This means that given the selected models and data, the probability of making an erroneous conclusion about increased risk is less than 1.4%.

A broader approach that takes into account various models and sensitivity analyses confirmed that with a posterior probability of 94.4%, the odds ratio of death when using cefepime exceeds one. Thus, regardless of the chosen analytical settings, the risk remains statistically significant.

Interpretation and recommendations

The authors emphasize that the results do not imply an immediate abandonment of cefepime in clinical practice. The drug remains an important tool in the fight against severe infections; however, it is necessary to reconsider its dosing regimens to minimize potential harm.

Dose optimization may include more accurate calculation of the drug volume based on the patient's kidney function, adjustment of administration intervals, and monitoring of antibiotic levels in plasma. Such measures can reduce toxicity without compromising therapeutic effectiveness.

For doctors and specialists in infectious diseases, the study results serve as a signal to revise treatment protocols. Additional randomized studies focused on the pharmacokinetic and pharmacodynamic parameters of cefepime may help clarify optimal usage regimens.

Source: N+1